Over the past 12 months, 7 insiders at Centessa Pharmaceuticals plc filed 39 open-market SEC Form 4 transactions on CNTA: 0 purchases worth $0 and 39 sales worth $20.0M. Insiders have been net sellers over this period. The most recent filing was on Jun 24, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 24, 26 | Index Ventures Life VI (jersey) L.p. | SELL | 9.81M | - | $0 |
| Jun 24, 26 | Medicxi Ventures Management (jersey) Ltd | SELL | 11.20M | - | $0 |
| Mar 26, 26 | Karen M. AndersonChief People Officer | SELL | 41.1K | $30.12 | $1.2M |
| Mar 26, 26 | Gregory M WeinhoffChief Business Officer | SELL | 24.0K | $30.00 | $720K |
| Mar 17, 26 | Karen M. AndersonChief People Officer | SELL | 10.0K | $28.10 | $282K |
| Mar 16, 26 | Karen M. AndersonChief People Officer | SELL | 64.8K | $28.21 | $1.8M |
| Mar 13, 26 | Karen M. AndersonChief People Officer | SELL | 108.0K | $27.13 | $2.8M |
| Mar 13, 26 | Gregory M WeinhoffChief Business Officer | SELL | 61.3K | $27.16 | $1.6M |
| Feb 2, 26 | Iqbal J HussainChief Legal Officer | SELL | 39.0K | $25.15 | $980K |
| Jan 30, 26 | Iqbal J HussainChief Legal Officer | SELL | 1.0K | $25.01 | $25K |
| Dec 9, 25 | Mario Alberto AccardiPresident, Orexin Program | SELL | 7.4K | $29.21 | $213K |
| Dec 8, 25 | Mario Alberto AccardiPresident, Orexin Program | SELL | 10.0K | $30.00 | $300K |
| Nov 17, 25 | Tia L BushChief Technology & Quality Ofc | SELL | 40.0K | $28.00 | $1.1M |
| Nov 17, 25 | Iqbal J HussainGeneral Counsel | SELL | 6.0K | $27.64 | $166K |
| Nov 12, 25 | Tia L BushChief Technology & Quality Ofc | SELL | 40.0K | $26.00 | $1.0M |
| Oct 27, 25 | Mario Alberto AccardiPresident, Orexin Program | SELL | 8.0K | $25.00 | $200K |
| Oct 15, 25 | Iqbal J HussainGeneral Counsel | SELL | 6.0K | $22.41 | $134K |
| Sep 24, 25 | Tia L BushChief Technology & Quality Ofc | SELL | 35.0K | $24.00 | $840K |
| Sep 16, 25 | Mario Alberto AccardiPresident, Orexin Program | SELL | 7.4K | $22.02 | $158K |
| Sep 15, 25 | Iqbal J HussainGeneral Counsel | SELL | 6.0K | $21.85 | $131K |
| Sep 10, 25 | Tia L BushChief Technology & Quality Ofc | SELL | 25.0K | $22.00 | $550K |
| Sep 10, 25 | Iqbal J HussainGeneral Counsel | SELL | 20.0K | $22.00 | $440K |
| Sep 9, 25 | Mario Alberto AccardiPresident, Orexin Program | SELL | 7.0K | $20.00 | $140K |
| Sep 9, 25 | Tia L BushChief Technology & Quality Ofc | SELL | 24.8K | $20.00 | $496K |
| Sep 9, 25 | Iqbal J HussainGeneral Counsel | SELL | 20.0K | $20.01 | $400K |
| Aug 15, 25 | Iqbal J HussainGeneral Counsel | SELL | 6.0K | $17.23 | $103K |
| Jul 29, 25 | Mario Alberto AccardiPresident, Orexin Program | SELL | 8.3K | $15.23 | $127K |
| Jul 25, 25 | Gregory M WeinhoffChief Business Officer | SELL | 10.0K | $15.56 | $156K |
| Jul 21, 25 | Saurabh SahaChief Executive Officer | SELL | 55.0K | $15.92 | $876K |
| Jul 15, 25 | Iqbal J HussainGeneral Counsel | SELL | 6.0K | $14.93 | $90K |
| Jun 25, 25 | Gregory M WeinhoffChief Business Officer | SELL | 10.0K | $13.86 | $139K |
| Jun 24, 25 | Mario Alberto AccardiPresident, Orexin Program | SELL | 15.0K | $14.00 | $210K |
| Jun 24, 25 | Iqbal J HussainGeneral Counsel | SELL | 12.0K | $14.02 | $168K |
| Jun 20, 25 | Saurabh SahaChief Executive Officer | SELL | 55.0K | $12.63 | $695K |
| May 27, 25 | Gregory M WeinhoffChief Business Officer | SELL | 10.0K | $12.82 | $128K |
| May 20, 25 | Saurabh SahaChief Executive Officer | SELL | 55.0K | $12.71 | $699K |
| May 16, 25 | Arjun GoyalDirector | BUY | 417.6K | $12.73 | $5.3M |
| May 15, 25 | Arjun GoyalDirector | BUY | 44.9K | $12.24 | $550K |
| May 1, 25 | Iqbal J HussainGeneral Counsel | SELL | 311 | $14.00 | $4K |
| Apr 28, 25 | Iqbal J HussainGeneral Counsel | SELL | 2.1K | $14.01 | $29K |
| Apr 25, 25 | Iqbal J HussainGeneral Counsel | SELL | 3.6K | $14.00 | $51K |
| Apr 25, 25 | Gregory M WeinhoffChief Business Officer | SELL | 11.7K | $13.61 | $160K |
| Apr 22, 25 | Saurabh SahaChief Executive Officer | SELL | 40.3K | $12.43 | $501K |
| Apr 21, 25 | Saurabh SahaChief Executive Officer | SELL | 14.7K | $12.29 | $180K |
| Mar 25, 25 | Gregory M WeinhoffChief Business Officer | SELL | 10.0K | $16.34 | $163K |
| Mar 20, 25 | Saurabh SahaChief Executive Officer | SELL | 55.0K | $16.69 | $918K |
| Mar 17, 25 | David M ChaoChief Administrative Officer | SELL | 5.5K | $17.50 | $94K |
| Mar 17, 25 | Iqbal J HussainGeneral Counsel | SELL | 6.0K | $16.45 | $99K |
| Feb 25, 25 | Gregory M WeinhoffChief Business Officer | SELL | 11.5K | $15.25 | $175K |
| Feb 20, 25 | Saurabh SahaChief Executive Officer | SELL | 54.2K | $16.54 | $863K |
Over the past 12 months, insiders at Centessa Pharmaceuticals plc filed 0 open-market purchases worth $0 and 39 sales worth $20.0M on CNTA, which makes them net sellers over the period. The most recent Form 4 was filed on Jun 24, 26.
The largest recent open-market CNTA insider purchase in our data was $5.3M by Arjun Goyal, Director, filed on May 16, 25.
7 different insiders at Centessa Pharmaceuticals plc filed open-market SEC Form 4 transactions on CNTA over the last 12 months.
InsiderTape plots every CNTA insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Centessa Pharmaceuticals plc insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →